Johnson & Johnson (NYSE:JNJ) Shares Sold by Harvey Investment Co. LLC

Harvey Investment Co. LLC trimmed its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 0.3% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 217,848 shares of the company’s stock after selling 657 shares during the period. Johnson & Johnson accounts for approximately 4.1% of Harvey Investment Co. LLC’s holdings, making the stock its 7th largest holding. Harvey Investment Co. LLC’s holdings in Johnson & Johnson were worth $34,145,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. DORCHESTER WEALTH MANAGEMENT Co boosted its position in Johnson & Johnson by 8.6% in the 1st quarter. DORCHESTER WEALTH MANAGEMENT Co now owns 67,618 shares of the company’s stock valued at $14,975,000 after buying an additional 5,327 shares during the last quarter. Cantor Fitzgerald Investment Advisor L.P boosted its position in Johnson & Johnson by 88.9% in the 1st quarter. Cantor Fitzgerald Investment Advisor L.P now owns 175,194 shares of the company’s stock valued at $31,049,000 after buying an additional 82,429 shares during the last quarter. AMI Investment Management Inc. boosted its position in Johnson & Johnson by 8.8% in the 1st quarter. AMI Investment Management Inc. now owns 18,305 shares of the company’s stock valued at $3,244,000 after buying an additional 1,475 shares during the last quarter. Equitable Holdings Inc. boosted its position in Johnson & Johnson by 4.9% in the 1st quarter. Equitable Holdings Inc. now owns 45,673 shares of the company’s stock valued at $8,095,000 after buying an additional 2,119 shares during the last quarter. Finally, USS Investment Management Ltd boosted its position in Johnson & Johnson by 2.4% in the 1st quarter. USS Investment Management Ltd now owns 860,371 shares of the company’s stock valued at $152,488,000 after buying an additional 20,528 shares during the last quarter. 69.55% of the stock is owned by institutional investors and hedge funds.

Insider Activity at Johnson & Johnson

In related news, major shareholder & Johnson Johnson sold 3,725 shares of Johnson & Johnson stock in a transaction dated Friday, February 16th. The stock was sold at an average price of $25.81, for a total value of $96,142.25. Following the sale, the insider now owns 4,099,575 shares of the company’s stock, valued at $105,810,030.75. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. In related news, EVP Jennifer L. Taubert sold 59,397 shares of Johnson & Johnson stock in a transaction dated Friday, February 9th. The stock was sold at an average price of $156.27, for a total value of $9,281,969.19. Following the sale, the executive vice president now owns 141,416 shares of the company’s stock, valued at $22,099,078.32. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, major shareholder & Johnson Johnson sold 3,725 shares of Johnson & Johnson stock in a transaction dated Friday, February 16th. The shares were sold at an average price of $25.81, for a total value of $96,142.25. Following the completion of the sale, the insider now directly owns 4,099,575 shares in the company, valued at approximately $105,810,030.75. The disclosure for this sale can be found here. 0.16% of the stock is owned by company insiders.

Johnson & Johnson Stock Performance

JNJ opened at $150.19 on Thursday. The business’s 50-day moving average price is $157.61 and its two-hundred day moving average price is $156.14. Johnson & Johnson has a 1 year low of $144.95 and a 1 year high of $175.97. The company has a market capitalization of $361.92 billion, a price-to-earnings ratio of 10.88, a P/E/G ratio of 2.55 and a beta of 0.53. The company has a debt-to-equity ratio of 0.38, a current ratio of 1.16 and a quick ratio of 0.91.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings results on Tuesday, January 23rd. The company reported $2.29 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.28 by $0.01. Johnson & Johnson had a return on equity of 37.27% and a net margin of 37.79%. The firm had revenue of $21.40 billion for the quarter, compared to the consensus estimate of $21.02 billion. During the same quarter last year, the business posted $2.35 EPS. The company’s revenue for the quarter was down 9.7% on a year-over-year basis. Equities analysts expect that Johnson & Johnson will post 10.65 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research analysts have recently issued reports on JNJ shares. Raymond James raised their price target on Johnson & Johnson from $172.00 to $175.00 and gave the stock an “outperform” rating in a research report on Wednesday, January 3rd. Royal Bank of Canada restated an “outperform” rating and issued a $181.00 price target on shares of Johnson & Johnson in a research report on Wednesday, February 28th. StockNews.com upgraded Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research report on Tuesday, February 6th. Cantor Fitzgerald reiterated an “overweight” rating and set a $215.00 target price on shares of Johnson & Johnson in a report on Wednesday, March 13th. Finally, Wells Fargo & Company lowered Johnson & Johnson from an “overweight” rating to an “equal weight” rating and reduced their target price for the stock from $170.00 to $163.00 in a report on Wednesday, December 13th. Seven equities research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, Johnson & Johnson currently has an average rating of “Moderate Buy” and an average target price of $177.31.

Johnson & Johnson Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.